CRMD
CorMedix Inc.
CRMD offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CRMD overall, supported by lower modeled downside and stronger modeled upside.
CRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.5x | $2.52 | -48% |
| Fair | 3.9x | $2.83 | -41% |
| Current | 6.6x | $4.84 | — |
| Expensive | 18x | $13.42 | +177% |
Historical ranges are pointers, not guarantees.
CRMD's PE is in its expensive range at 6.6x.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over CRMD in the historical PE scenario, which offers more potential upside but is not a forecast.
CRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over CRMD on the outlook, with more favorable earnings and revenue expectations.
CRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.73 | -65% |
| Q2 2026 | $2.18 | +179% |
| Q1 2026 | $2.17 | +768% |
| Q4 2025 | $2.04 | +$2.34 |
| Q3 2025 | $2.09 | +$2.89 |
| Q2 2025 | $0.78 | +$1.70 |
| Q1 2025 | $0.25 | +$1.17 |
| Q4 2024 | -$0.30 | +$0.61 |
CRMD has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
CRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.5M | -48% |
| Q2 2026 | $101.9M | +157% |
| Q1 2026 | $127.4M | +226% |
| Q4 2025 | $128.6M | +312% |
| Q3 2025 | $104.3M | +810% |
| Q2 2025 | $39.7M | +4829% |
| Q4 2022 | $29.7K | -47% |
| Q3 2022 | $6.8K | -82% |
CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -61 points |
| Q2 2026 | 42% | -7.1 points |
| Q1 2026 | 50% | -1.5 points |
| Q4 2025 | 46% | +4.5 points |
| Q3 2025 | 49% | +78 points |
| Q2 2025 | 49% | +1947 points |
| Q1 2025 | 52% | N/A |
| Q4 2024 | 41% | N/A |
CRMD's operating margin was −12% last quarter, down 61 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CRMD on profitability, with a higher operating margin.
CRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.8M | +189% |
| Q2 2026 | $85.7M | +186% |
| Q1 2026 | $41.7M | +111% |
| Q4 2025 | $92.7M | +$98.4M |
| Q3 2025 | $30.4M | +$44M |
| Q2 2025 | $30M | +$44M |
| Q1 2025 | $19.7M | +$37.1M |
| Q4 2024 | -$5.6M | +$5.4M |
CRMD has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -15% | -14M shares |
| 1 year | +9.1% | +6.5M shares |
| 3 years | +73% | +33.1M shares |
| 5 years | +106% | +40.4M shares |
| Available history | +225% | +54.3M shares |
CRMD has 78M diluted shares, up 9.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.4M |
| Q1 2026 | $11.1M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
CRMD has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.7 | Oversold |
CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRMD PE vs Healthcare Sector
| Metric | CRMD | Sector median | Relative |
|---|---|---|---|
| PE | 6.6x | 26x | 74% below |
| PE % | 66 | 29 | 37 pts above |
CRMD has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.67 | 27% below |
| 20 week MA | $7.49 | 35% below |
| 50 week MA | $7.91 | 39% below |
| 100 week MA | $9.41 | 49% below |
| 200 week MA | $7.22 | 33% below |
CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CRMD on trend strength, trading above more of its moving averages.
CRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.14 | $7.87 | +10% |
| 2021 | $7.87 | $4.98 | -37% |
| 2022 | $4.98 | $4.11 | -17% |
| 2023 | $4.11 | $3.76 | -8.5% |
| 2024 | $3.76 | $8.21 | +118% |
| 2025 | $8.21 | $12.5 | +53% |
| 2026 YTD | $12.5 | $4.84 | -61% |
CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRMD on returns for 2026, with the stronger performance.